Literature DB >> 28786415

Sarcoma: Does histotype-tailored neoadjuvant therapy improve outcomes?

Robin L Jones1, Khin Thway1.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28786415     DOI： 10.1038/nrclinonc.2017.118

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  8 in total

1.  A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma.

Authors:  Nabeel Pervaiz; Nigel Colterjohn; Forough Farrokhyar; Richard Tozer; Alvaro Figueredo; Michelle Ghert
Journal:  Cancer       Date:  2008-08-01       Impact factor: 6.860

Review 2.  Histology-Driven Therapy: The Importance of Diagnostic Accuracy in Guiding Systemic Therapy of Soft Tissue Tumors.

Authors:  Jonathan Noujaim; Khin Thway; Amna Sheri; Charles Keller; Robin L Jones
Journal:  Int J Surg Pathol       Date:  2015-09-22       Impact factor: 1.271

3.  A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma.

Authors:  E Gortzak; A Azzarelli; J Buesa; V H Bramwell; F van Coevorden; A N van Geel; A Ezzat; A Santoro; J W Oosterhuis; M van Glabbeke; A Kirkpatrick; J Verweij
Journal:  Eur J Cancer       Date:  2001-06       Impact factor: 9.162

4.  Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.

Authors:  Alessandro Gronchi; Stefano Ferrari; Vittorio Quagliuolo; Javier Martin Broto; Antonio Lopez Pousa; Giovanni Grignani; Umberto Basso; Jean-Yves Blay; Oscar Tendero; Robert Diaz Beveridge; Virginia Ferraresi; Iwona Lugowska; Domenico Franco Merlo; Valeria Fontana; Emanuela Marchesi; Davide Maria Donati; Elena Palassini; Emanuela Palmerini; Rita De Sanctis; Carlo Morosi; Silvia Stacchiotti; Silvia Bagué; Jean Michelle Coindre; Angelo Paolo Dei Tos; Piero Picci; Paolo Bruzzi; Paolo Giovanni Casali
Journal:  Lancet Oncol       Date:  2017-05-09       Impact factor: 41.316

5.  Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration.

Authors: 
Journal:  Lancet       Date:  1997-12-06       Impact factor: 79.321

6.  High-grade soft-tissue sarcomas: tumor response assessment--pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria.

Authors:  Silvia Stacchiotti; Paola Collini; Antonella Messina; Carlo Morosi; Marta Barisella; Rossella Bertulli; Claudio Piovesan; Palma Dileo; Valter Torri; Alessandro Gronchi; Paolo Giovanni Casali
Journal:  Radiology       Date:  2009-03-04       Impact factor: 11.105

7.  Evaluation of response after neoadjuvant treatment in soft tissue sarcomas; the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) recommendations for pathological examination and reporting.

Authors:  E Wardelmann; R L Haas; J V M G Bovée; Ph Terrier; A Lazar; C Messiou; C LePechoux; W Hartmann; F Collin; C Fisher; G Mechtersheimer; A P DeiTos; S Stacchiotti; R L Jones; A Gronchi; S Bonvalot
Journal:  Eur J Cancer       Date:  2015-12-14       Impact factor: 9.162

8.  Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial.

Authors:  Penella J Woll; Peter Reichardt; Axel Le Cesne; Sylvie Bonvalot; Alberto Azzarelli; Harald J Hoekstra; Michael Leahy; Frits Van Coevorden; Jaap Verweij; Pancras C W Hogendoorn; Monia Ouali; Sandrine Marreaud; Vivien H C Bramwell; Peter Hohenberger
Journal:  Lancet Oncol       Date:  2012-09-04       Impact factor: 41.316
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.